Abliva AB (publ) (ABLI.ST)
SEK 0.44
(0.23%)
SEK 0.44
(0.23%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -93.6 Million SEK | -9.08% |
| 2022 | -79.89 Million SEK | 33.57% |
| 2021 | -120.82 Million SEK | -109.79% |
| 2020 | -57.43 Million SEK | 23.01% |
| 2019 | -76.41 Million SEK | -9.61% |
| 2018 | -73.25 Million SEK | 2.47% |
| 2017 | -70.06 Million SEK | -41.13% |
| 2016 | -70.75 Million SEK | 18.83% |
| 2015 | -89.6 Million SEK | -39.7% |
| 2014 | -44.23 Million SEK | -96.8% |
| 2013 | -21.77 Million SEK | -35.6% |
| 2012 | -15.77 Million SEK | -76.51% |
| 2011 | -9.27 Million SEK | -126.18% |
| 2010 | -4.1 Million SEK | -171.55% |
| 2009 | -1.47 Million SEK | 3.13% |
| 2008 | -1.55 Million SEK | -27.73% |
| 2007 | -1.22 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -24.92 Million SEK | -42.76% |
| 2024 Q1 | -18.52 Million SEK | 28.59% |
| 2023 Q2 | -20.63 Million SEK | -34.36% |
| 2023 FY | - SEK | -9.08% |
| 2023 Q1 | -15.36 Million SEK | 9.24% |
| 2023 Q3 | -24.4 Million SEK | -18.25% |
| 2023 Q4 | -24.18 Million SEK | 0.89% |
| 2022 Q2 | -17.66 Million SEK | 15.64% |
| 2022 FY | - SEK | 33.57% |
| 2022 Q4 | -16.92 Million SEK | 31.35% |
| 2022 Q1 | -20.94 Million SEK | 41.96% |
| 2022 Q3 | -24.65 Million SEK | -39.54% |
| 2021 Q1 | -20.79 Million SEK | -67.07% |
| 2021 Q3 | -34.18 Million SEK | -15.3% |
| 2021 Q4 | -36.08 Million SEK | -5.54% |
| 2021 FY | - SEK | -109.79% |
| 2021 Q2 | -29.65 Million SEK | -42.61% |
| 2020 Q3 | -9.41 Million SEK | 52.11% |
| 2020 FY | - SEK | 23.01% |
| 2020 Q4 | -12.44 Million SEK | -32.14% |
| 2020 Q2 | -19.66 Million SEK | -23.68% |
| 2020 Q1 | -15.9 Million SEK | 39.74% |
| 2019 FY | - SEK | -9.61% |
| 2019 Q3 | -14.67 Million SEK | 27.27% |
| 2019 Q1 | -13.24 Million SEK | 20.48% |
| 2019 Q4 | -26.39 Million SEK | -79.84% |
| 2019 Q2 | -20.17 Million SEK | -52.37% |
| 2018 Q3 | -14.48 Million SEK | 40.8% |
| 2018 Q2 | -24.46 Million SEK | -95.38% |
| 2018 Q1 | -12.52 Million SEK | 16.65% |
| 2018 FY | - SEK | 2.47% |
| 2018 Q4 | -16.65 Million SEK | -14.98% |
| 2017 FY | - SEK | -41.13% |
| 2017 Q4 | -15.02 Million SEK | -21.45% |
| 2017 Q3 | -12.37 Million SEK | 42.55% |
| 2017 Q2 | -21.53 Million SEK | -2.57% |
| 2017 Q1 | -20.99 Million SEK | -47.73% |
| 2016 FY | - SEK | 18.83% |
| 2016 Q1 | -10.6 Million SEK | -58.41% |
| 2016 Q4 | -14.21 Million SEK | 58.1% |
| 2016 Q3 | -33.91 Million SEK | -188.31% |
| 2016 Q2 | -11.76 Million SEK | -10.87% |
| 2015 Q3 | -53.41 Million SEK | -256.23% |
| 2015 FY | - SEK | -39.7% |
| 2015 Q4 | -6.69 Million SEK | 87.46% |
| 2015 Q1 | -14.05 Million SEK | 13.22% |
| 2015 Q2 | -14.99 Million SEK | -6.67% |
| 2014 Q2 | -14.05 Million SEK | -43.14% |
| 2014 FY | - SEK | -96.8% |
| 2014 Q1 | -9.82 Million SEK | -6.19% |
| 2014 Q4 | -16.19 Million SEK | -348.35% |
| 2014 Q3 | -3.61 Million SEK | 74.3% |
| 2013 Q4 | -9.24 Million SEK | -39.36% |
| 2013 FY | - SEK | -35.6% |
| 2013 Q3 | -6.63 Million SEK | -345.37% |
| 2013 Q2 | -1.49 Million SEK | 69.12% |
| 2013 Q1 | -4.82 Million SEK | 9.03% |
| 2012 Q2 | -4.1 Million SEK | -45.02% |
| 2012 Q3 | -4.13 Million SEK | -0.71% |
| 2012 Q4 | -5.3 Million SEK | -28.33% |
| 2012 FY | - SEK | -76.51% |
| 2012 Q1 | -2.83 Million SEK | -12.04% |
| 2011 Q2 | -3.01 Million SEK | -115.37% |
| 2011 Q4 | -2.52 Million SEK | -8.18% |
| 2011 FY | - SEK | -126.18% |
| 2011 Q1 | -1.39 Million SEK | -6.26% |
| 2011 Q3 | -2.33 Million SEK | 22.55% |
| 2010 Q3 | -1.43 Million SEK | -73.91% |
| 2010 Q1 | -520.29 Thousand SEK | -9.74% |
| 2010 Q4 | -1.31 Million SEK | 8.32% |
| 2010 FY | - SEK | -171.55% |
| 2010 Q2 | -826.2 Thousand SEK | -58.8% |
| 2009 Q2 | -401.74 Thousand SEK | -18.12% |
| 2009 Q3 | -294.12 Thousand SEK | 26.79% |
| 2009 Q4 | -474.12 Thousand SEK | -61.2% |
| 2009 FY | - SEK | 3.13% |
| 2009 Q1 | -340.1 Thousand SEK | 0.0% |
| 2008 FY | - SEK | -27.73% |
| 2007 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Simris Alg AB (publ) | -22.36 Million SEK | -318.584% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 70.514% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 66.81% |
| Xintela AB (publ) | -53.47 Million SEK | -75.063% |
| Active Biotech AB (publ) | -43.88 Million SEK | -113.293% |
| Amniotics AB (publ) | -27.14 Million SEK | -244.87% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -558.423% |
| BioArctic AB (publ) | 275.38 Million SEK | 133.991% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 74.549% |
| Camurus AB (publ) | 562.54 Million SEK | 116.64% |
| Cantargia AB (publ) | -284.31 Million SEK | 67.076% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -378.104% |
| CombiGene AB (publ) | -35.33 Million SEK | -164.908% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 33.541% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -447.911% |
| Genovis AB (publ.) | 64.57 Million SEK | 244.967% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 18.536% |
| Mendus AB (publ) | -97.84 Million SEK | 4.331% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -152.831% |
| Intervacc AB (publ) | -68.98 Million SEK | -35.703% |
| Kancera AB (publ) | -61.88 Million SEK | -51.251% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -249.505% |
| LIDDS AB (publ) | -39.67 Million SEK | -135.967% |
| Lipum AB (publ) | -37.11 Million SEK | -152.184% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -673.364% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 398.077% |
| NextCell Pharma AB | -40.98 Million SEK | -128.395% |
| OncoZenge AB (publ) | 7.26 Million SEK | 1388.302% |
| Saniona AB (publ) | -69.69 Million SEK | -34.311% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 44.876% |
| Ziccum AB (publ) | -20.34 Million SEK | -360.171% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 4680500.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 60.605% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -4400.385% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -596.955% |
| Corline Biomedical AB | -1.69 Million SEK | -5435.659% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 45.992% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -70.799% |
| Aptahem AB (publ) | -10 Million SEK | -835.217% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 910.529% |
| Fluicell AB (publ) | -25.91 Million SEK | -261.226% |
| Biovica International AB (publ) | -119.5 Million SEK | 21.671% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -121.694% |
| AcouSort AB (publ) | -16.7 Million SEK | -460.426% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 70.665% |
| 2cureX AB (publ) | -35.13 Million SEK | -166.416% |
| I-Tech AB | 30.34 Million SEK | 408.479% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 86.9% |
| Cyxone AB (publ) | -20.41 Million SEK | -358.548% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 8.633% |
| Biosergen AB | 228 Thousand SEK | 41156.14% |
| Nanologica AB (publ) | -62.11 Million SEK | -50.691% |
| SynAct Pharma AB | -222.7 Million SEK | 57.967% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -113.42% |
| BioInvent International AB (publ) | -312.7 Million SEK | 70.065% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 30353.415% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 222981.497% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 59.586% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -962.221% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 13.771% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -716.183% |